Ptc Therapeutics (PTCT) Share-based Compensation (2012 - 2026)

Ptc Therapeutics' Share-based Compensation history runs 15 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 29.68% year-over-year to $23.4 million in Q1 2026; TTM through Mar 2026 was $79.9 million, a 7.55% increase from a year earlier, with the FY2025 full-year figure at $129.8 million, up 31.11% from the prior year.
• Share-based Compensation rose to $23.4 million in Q1 2026 per PTCT's latest filing, from $18.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $29.4 million in Q2 2023 and bottomed at $523000.0 in Q4 2022.
• The 5-year median for Share-based Compensation is $19.6 million (2024), against an average of $21.3 million.
• Across the five-year window, Share-based Compensation tumbled 98.01% in 2022 and climbed 29.68% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $523000.0 in 2022, then soared by 5051.43% to $26.9 million in 2023, then plunged by 36.01% to $17.2 million in 2024, then rose by 7.42% to $18.5 million in 2025, then advanced by 26.48% to $23.4 million in 2026.
• Per Business Quant, the three latest PTCT Share-based Compensation figures stand at $23.4 million (Q1 2026), $18.5 million (Q4 2025), and $19.4 million (Q3 2025).